Medical Management of Primary Aldosteronism for Elevated Blood Pressure

Diagnostic Classification and Treatment Approach

Primary aldosteronism is the most common form of secondary hypertension, with approximately 50% of cases being unilateral and 50% bilateral, according to the European Heart Journal and the Journal of the American College of Cardiology 1, 2
The management approach depends critically on whether the condition is unilateral or bilateral, determined through adrenal vein sampling or functional imaging with radiolabeled tracers, as recommended by the European Heart Journal 1
Unilateral disease is potentially curable with surgery, while bilateral disease requires lifelong medical therapy, as stated by the European Heart Journal and the Journal of the American College of Cardiology 1, 3

The European Heart Journal recommends spironolactone as the first-line agent for bilateral primary aldosteronism, at doses of 50-100 mg daily, which can be titrated up to 300-400 mg daily if necessary 1
The Journal of the American College of Cardiology suggests that laparoscopic adrenalectomy is the treatment of choice for unilateral primary aldosteronism 2, 3
Medical therapy with MRAs is indicated for unilateral primary aldosteronism when the patient is not a surgical candidate or declines surgery, as recommended by the European Heart Journal and the Journal of the American College of Cardiology 1, 2

Early diagnosis and treatment improve cure rates and reduce target organ damage, according to the European Heart Journal and Circulation 1, 4
The European Heart Journal states that MRAs can reverse aldosterone-specific target organ damage, including left ventricular hypertrophy, albuminuria, and carotid intima-media thickness 1

Delayed diagnosis can lead to vascular remodeling that affects renal function and may cause residual hypertension even after appropriate treatment, as warned by the European Heart Journal 1
The European Heart Journal notes that spironolactone can cause hyperkalemia, especially in patients with reduced renal function, and that careful monitoring is essential 1

Complex cases or rare forms of primary aldosteronism should be referred to specialized hypertension centers, as recommended by the European Heart Journal and Praxis Medical Insights 1, 5

The American College of Cardiology recommends medical management with mineralocorticoid receptor antagonists (spironolactone or eplerenone) as the preferred approach for an 81-year-old female with multiple comorbidities and hyperaldosteronism, rather than surgery 6
For an 81-year-old with multiple comorbidities, proceed directly to medical therapy regardless of disease laterality due to surgical risk 7, 8

Medical therapy achieves equivalent long-term outcomes to surgery in terms of blood pressure control, cardiovascular outcomes, and kidney function, with blood pressure improvement in virtually 100% of patients when treated with adequate doses of MRA 6
Complete normalization of blood pressure occurs in approximately 50% of patients, similar to surgical cure rates 6

Perioperative cardiovascular risk is substantially elevated in elderly patients with multiple comorbidities undergoing noncardiac surgery 9

Annual assessment of blood pressure control and medication tolerance is recommended 8

The American Heart Association recommends starting eplerenone at a dose substantially higher than that used for heart failure, reflecting the different pathophysiology and treatment goals in primary aldosteronism, with a starting dose of 50-100 mg daily 10
The initial dose of eplerenone for primary aldosteronism is higher than the 25 mg daily used for heart failure, due to the different treatment goals and pathophysiology, with lower heart failure doses being inadequate for treating autonomous aldosterone excess in primary aldosteronism 10

The American College of Cardiology recommends checking potassium and creatinine within 2-3 days and again at 7 days after initiation or dose increases of eplerenone, with continued monthly monitoring for the first 3 months, then every 3 months thereafter 10
If potassium rises above 5.5 mEq/L, the European Society of Cardiology suggests halving the dose or switching to alternate-day dosing 11
The American Heart Association recommends discontinuing eplerenone if potassium exceeds 6.0 mEq/L or creatinine rises above 2.5 mg/dL in men or 2.0 mg/dL in women 10